Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 136

Similar articles for PubMed (Select 19858367)


Contralateral breast cancer in BRCA1/BRCA2 mutation carriers: the story of the other side.

Garber JE, Golshan M.

J Clin Oncol. 2009 Dec 10;27(35):5862-4. doi: 10.1200/JCO.2009.25.1652. Epub 2009 Oct 26. No abstract available.


Contralateral breast cancer risk in BRCA1 and BRCA2 mutation carriers.

Graeser MK, Engel C, Rhiem K, Gadzicki D, Bick U, Kast K, Froster UG, Schlehe B, Bechtold A, Arnold N, Preisler-Adams S, Nestle-Kraemling C, Zaino M, Loeffler M, Kiechle M, Meindl A, Varga D, Schmutzler RK.

J Clin Oncol. 2009 Dec 10;27(35):5887-92. doi: 10.1200/JCO.2008.19.9430. Epub 2009 Oct 26.


Breast cancer risks in individuals testing negative for a known family mutation in BRCA1 or BRCA2.

Domchek SM, Gaudet MM, Stopfer JE, Fleischaut MH, Powers J, Kauff N, Offit K, Nathanson KL, Robson M.

Breast Cancer Res Treat. 2010 Jan;119(2):409-14. doi: 10.1007/s10549-009-0611-y.


Frequent somatic mutations of GATA3 in non-BRCA1/BRCA2 familial breast tumors, but not in BRCA1-, BRCA2- or sporadic breast tumors.

Arnold JM, Choong DY, Thompson ER; kConFab, Waddell N, Lindeman GJ, Visvader JE, Campbell IG, Chenevix-Trench G.

Breast Cancer Res Treat. 2010 Jan;119(2):491-6. doi: 10.1007/s10549-008-0269-x. Epub 2009 Feb 3.


Tamoxifen and risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers: a case-control study. Hereditary Breast Cancer Clinical Study Group.

Narod SA, Brunet JS, Ghadirian P, Robson M, Heimdal K, Neuhausen SL, Stoppa-Lyonnet D, Lerman C, Pasini B, de los Rios P, Weber B, Lynch H; Hereditary Breast Cancer Clinical Study Group.

Lancet. 2000 Dec 2;356(9245):1876-81.


MDM2 SNP309 accelerates breast and ovarian carcinogenesis in BRCA1 and BRCA2 carriers of Jewish-Ashkenazi descent.

Yarden RI, Friedman E, Metsuyanim S, Olender T, Ben-Asher E, Papa MZ.

Breast Cancer Res Treat. 2008 Oct;111(3):497-504. Epub 2007 Nov 18.


BRCA1 and BRCA2 mutations in breast and ovarian cancer syndrome: reflection on the Creighton University historical series of high risk families.

Sinilnikova OM, Mazoyer S, Bonnardel C, Lynch HT, Narod SA, Lenoir GM.

Fam Cancer. 2006;5(1):15-20. Review.


Population-based study of the risk of second primary contralateral breast cancer associated with carrying a mutation in BRCA1 or BRCA2.

Malone KE, Begg CB, Haile RW, Borg A, Concannon P, Tellhed L, Xue S, Teraoka S, Bernstein L, Capanu M, Reiner AS, Riedel ER, Thomas DC, Mellemkjaer L, Lynch CF, Boice JD Jr, Anton-Culver H, Bernstein JL.

J Clin Oncol. 2010 May 10;28(14):2404-10. doi: 10.1200/JCO.2009.24.2495. Epub 2010 Apr 5.


The impact of contralateral mastectomy on mortality in BRCA1 and BRCA2 mutation carriers with breast cancer.

Narod SA.

Breast Cancer Res Treat. 2011 Jul;128(2):581-3. doi: 10.1007/s10549-011-1479-1. Epub 2011 Apr 1.


Management updates for women with a BRCA1 or BRCA2 mutation.

Nusbaum R, Isaacs C.

Mol Diagn Ther. 2007;11(3):133-44. Review.


Outcome of conservatively managed early-onset breast cancer by BRCA1/2 status.

Haffty BG, Harrold E, Khan AJ, Pathare P, Smith TE, Turner BC, Glazer PM, Ward B, Carter D, Matloff E, Bale AE, Alvarez-Franco M.

Lancet. 2002 Apr 27;359(9316):1471-7.


Pathologic characteristics of breast parenchyma in patients with hereditary breast carcinoma, including BRCA1 and BRCA2 mutation carriers.

Adem C, Reynolds C, Soderberg CL, Slezak JM, McDonnell SK, Sebo TJ, Schaid DJ, Myers JL, Sellers TA, Hartmann LC, Jenkins RB.

Cancer. 2003 Jan 1;97(1):1-11.


Intratumoral IGF-I protein expression is selectively upregulated in breast cancer patients with BRCA1/2 mutations.

Hudelist G, Wagner T, Rosner M, Fink-Retter A, Gschwantler-Kaulich D, Czerwenka K, Kroiss R, Tea M, Pischinger K, Köstler WJ, Attems J, Mueller R, Blaukopf C, Kubista E, Hengstschläger M, Singer CF.

Endocr Relat Cancer. 2007 Dec;14(4):1053-62.


A combined analysis of outcome following breast cancer: differences in survival based on BRCA1/BRCA2 mutation status and administration of adjuvant treatment.

Robson ME, Chappuis PO, Satagopan J, Wong N, Boyd J, Goffin JR, Hudis C, Roberge D, Norton L, Bégin LR, Offit K, Foulkes WD.

Breast Cancer Res. 2004;6(1):R8-R17. Epub 2003 Oct 24.


Response to neo-adjuvant chemotherapy in BRCA1 and BRCA2 related stage III breast cancer.

Hubert A, Mali B, Hamburger T, Rottenberg Y, Uziely B, Peretz T, Kadouri L.

Fam Cancer. 2009;8(3):173-7. doi: 10.1007/s10689-008-9223-7. Epub 2008 Nov 19.


High risk of contralateral breast carcinoma in women with hereditary/familial non-BRCA1/BRCA2 breast carcinoma.

Shahedi K, Emanuelsson M, Wiklund F, Gronberg H.

Cancer. 2006 Mar 15;106(6):1237-42.


Prophylactic mastectomy in BRCA1 and BRCA2 mutation carriers: very low risk for subsequent breast cancer.

Kaas R, Verhoef S, Wesseling J, Rookus MA, Oldenburg HS, Peeters MJ, Rutgers EJ.

Ann Surg. 2010 Mar;251(3):488-92. doi: 10.1097/SLA.0b013e3181c3c36d.


Lymphocyte radiosensitivity in BRCA1 and BRCA2 mutation carriers and implications for breast cancer susceptibility.

Barwell J, Pangon L, Georgiou A, Kesterton I, Langman C, Arden-Jones A, Bancroft E, Salmon A, Locke I, Kote-Jarai Z, Morris JR, Solomon E, Berg J, Docherty Z, Camplejohn R, Eeles R, Hodgson SV.

Int J Cancer. 2007 Oct 1;121(7):1631-6.


Spectrum and characterisation of BRCA1 and BRCA2 deleterious mutations in high-risk Czech patients with breast and/or ovarian cancer.

Machackova E, Foretova L, Lukesova M, Vasickova P, Navratilova M, Coene I, Pavlu H, Kosinova V, Kuklova J, Claes K.

BMC Cancer. 2008 May 20;8:140. doi: 10.1186/1471-2407-8-140.


BRCA1 and BRCA2: the genetic testing and the current management options for mutation carriers.

Palma M, Ristori E, Ricevuto E, Giannini G, Gulino A.

Crit Rev Oncol Hematol. 2006 Jan;57(1):1-23. Epub 2005 Dec 6. Review.

Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk